Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (October 2025)
24 slides from Chimeric Therapeutics's investor presentation, Oct 8, 2025
Slide 1: Pioneers in Cell Therapy
For personal use only CHI MERIC THE RAP EU TICS 25 20 PIONEERS IN CELL THERAPY CHIMERIC ASX: CHM
Slide 2: Disclaimer
DISCLAIMER Certain statements contained in this presentation, including, without contained herein to reflect future events or developments except as limitation, statements containing the words “believes,” “plans,” required by law. “expects,” “anticipates,” and words of similar import, constitute Thi
Slide 3: Investment Highlights and Corporate Profile
INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials For personal use only CORPORATE PROFILE Multiple clinical updates Exchange ASX: CHM CHI MERIC THE RAP EU TICS Experienced leadership team Share Price $0.003 52 Week Range $0.002 - 0.017 the FIRST CDH17 CAR-T in clinical trials Market Cap ~ 10m First
Slide 4: CHM Leadership Team
4 CHM LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION For personal use only CHI MERIC THE RAP EU TICS Dr Rebecca McQUALTER Dr Jason LITTEN Dr Stephanie ASTROW Chief Executive Officer Chief Medical Officer Chief Scientific Officer 50+ 50+ 5/7 EXPERTISE EXPERIENCE FDA-Approved
Slide 5: CHM: Broad Portfolio
5 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CORE-NK CHM CLTX CAR-T ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS PHASE 1B PHASE 1B TRIAL OPEN TRIAL OPEN PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL 4 sites active MD Anderson Case Western 1 site active 2
Slide 6: CHM CDH17
For personal use only CHI MERIC THE RAP EU TICS 25 20 CHM CDH17 ASX: CHM
Slide 7: CDH17 Overview
7 CDH17 OVERVIEW Over a decade of development at the world- renowned cell therapy centre, The University of For personal use only Pennsylvania Compelling pre-clinical efficacy in gastric, pancreatic and neuroendocrine Cancers Dr. Xianxin Hua, CHI MERIC THE RAP EU TICS Dr. Carl June M.D. M.D., Ph.D.
Slide 8: Encouraging Pre-Clinical Results
8 ENCOURAGING PRE-CLINICAL RESULTS CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models For personal use only NEUROENDOCRINE TUMOURS GASTRIC CANCER CHI MERIC THE RAP EU TICS PANCREATIC CANCER CHM CDH17 CAR-T 20 25 Source: Feng et al., Nature Cancer, 2022 C HI MER
Slide 9: CHM CDH17 CAR-T Phase 1/2 Recruiting
9 CHM CDH17 CAR-T PHASE 1 RECRUITING The first CDH17 CAR T cell therapy in clinical trials globally For personal use only PERSONALISED CAR-T: AUTOLOGOUS CHM CDH17 4 prestigious sites recruiting: Sarah Cannon, UPenn, Uchiacgo, Emory CAR-T CHI MERIC THE RAP EU TICS FDA IND clearance: Nov 23 FDA FASTRA
Slide 10: Phase 1/2 Clinical Trial of CHM CDH17 Design
Phase 1/2 Clinical Trial of CHM CDH17 Design For personal use only CHI MERIC THE RAP EU TICS 20 NCT06501183 25 C HI MERI C THERAPEUTI CS.C OM
Slide 11: CHM CDH17 Progress as at Oct 8th, 2025
11 CHM CDH17 PROGRESS AS AT OCT 8TH, 2025 For personal use only Dose Level Status Notes 1 50m Completed 4 patients treated 1 patient remains on study CHI MERIC THE RAP EU TICS 2 150m Recruitment Ongoing 4 patients treated 3 450m Recruitment underway 2 patients awaiting dosing assignment Manufacturin
Slide 12: Clinical Preliminary Results: Dose Level 1
CLINICAL PRELIMINARY RESULTS 12 DOSE LEVEL 1 COMPLETED For personal use only 50m Cells Tumour Type Status Patient 1 CRC No follow up CHI MERIC THE RAP EU TICS Patient 2 NET Stable Disease until day 150 progression Grade 1 CRS Patient 3 CRC Stable Disease at day 300. Patient 4 CRC Progressive Disease
Slide 13: Clinical Preliminary Results: Dose Level 2
CLINICAL PRELIMINARY RESULTS 13 DOSE LEVEL 2 Ongoing For personal use only 150m Cells Tumour Type Status Patient 5 CRC Stable Disease 90days Tumour Shrinkage 12% CHI MERIC THE RAP EU TICS Patient 6 NET Stable Disease Tumour Shrinkage 6%-37% Patient 7 CRC Treated. Patient 8 CRC Treated. 20 25 CRC= Co
Slide 14: CHM CDH17 Progress: Recruitment Underway
CHM CDH17 PROGRESS 14 RECRUITMENT UNDERWAY For personal use only TBD Dose of Cells Tumour Type Status Patient 9 NET Manufactured. Dose yet to be assigned CHI MERIC THE RAP EU TICS Patient 10 NET Manufactured. Dose yet to be assigned TBD TBD 20 25 CRC= Colorectal Cancer (Bowel Cancer) NET= NeuroEndoc
Slide 15: CHM CDH17 CAR-T Cells Expand and Persist
CHM CDH17 CAR-T cells expand and persist For personal use only CHI MERIC THE RAP EU TICS 20 25 C HI MERI C THERAPEUTI CS.C OM
Slide 16: Total Global Market Size
16 TOTAL GLOBAL MARKET SIZE For personal use only CHI MERIC THE RAP EU TICS 27.7Bin 2024 20 25 C HI MERI C THERAPEUTI CS.C OM
Slide 17: Summary + FY26 Catalysts
SUMMARY + FY26 CATALYSTS 8 patients treated For personal use only 10/10 manufacturing runs CHM CDH17 Anti-tumour activity observed CHM 2101 No safety issues to date CHI MERIC THE RAP EU TICS No off-target effects Complete Dose level 2 Commence Dose level 3 (if appropriate) Conclude Phase 1 Phase 2 r
Slide 18: CHM CORE NK
For personal use only CHI MERIC THE RAP EU TICS 25 20 CHM CORE NK ASX: CHM
Slide 19: CHM CORE-NK Phase 1b Trials Open
19 CHM CORE-NK 2 PHASE 1B TRIALS OPEN Phase 1b clinical trials OPEN For personal use only OFF THE SHELF: ALLOGENEIC CHM CORE-NK NK cell expansion platform: Universal Donor ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS Positive Phase 1A Clinical Trial in AML Two ongoing Phase 1B Clinical Trials in AML
Slide 20: AML Phase 1b Clinical Trial Open
20 AML PHASE 1B CLINICAL TRIAL OPEN CHM CORE-NK + AZA + VEN in FRONTLINE AML Clinical Trials.gov Identifier: NCT05834244 For personal use only CHI MERIC THE RAP EU TICS CORE NK CELLS FDA REGISTERED FDA REGISTERED CHEMOTHERAPY BLOOD CANCER DRUG 20 CHM CORE NK 25 ‘OFF THE SHELF’ NK C HI MERI C THERAPE
Slide 21: CHM CORE-NK Frontline Phase Study Results
21 CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS Four Completes Responses, 1 Partial Response For personal use only Dose escalation Relapse Refractory Patients completed 1 Complete Response CHI MERIC THE RAP EU TICS First line FrontLine Patients with no prior treatment Dosing 3 Complete Responses Unde
Slide 22: Summary CHM CORE-NK
SUMMARY CHM CORE-NK For personal use only Investigator Sponsored Trial – MD ANDERSON CHM CORE-NK Dose Escalation competed CHM CDH17 ‘OFF THE SHELF’ NK CHM 2101 First Line Dosing Underway – up to 20 patients CHI MERIC THE RAP EU TICS No safety issues to date Complete dosing of 20 patients; subject to
Slide 23: Summary
SUMMARY 8 patients treated For personal use only 10/10 manufacturing runs CHM CDH17 Tumour shrinkage observed 10 CHM 2101 No safety issues to date CHI MERIC THE RAP EU TICS No off-target effects Investigator Sponsored Trial – MD ANDERSON Dose Escalation completed CHM CORE-NK First Line Dosing Underw
Slide 24: Chimeric: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com ASX: CHM 20 25
Chimeric Therapeutics — Investor Presentation (October 2025) on 6ix